Openbookopenbook
Equity
Renalytix AI plc(RENX)
GBX --+0.00%
Reward36Moderate
Risk82High
📊75%Data
Revenue growing 14% YoY
RENX
+0.0 · +0.00%
GBX · LSE
Renalytix AI plc | Healthcare
Capital Destroyer
Market Cap:14.64M
ℹ️
Reward Rating
36
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
82
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on RENX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 88p.

What is Renalytix AI plc?

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States.

RENX · Verdict

Limited reward · high risk

RENX has limited near-term tailwinds — profitability and cash flow weigh on the model output.

Based on 88% data coverage

RENX · Verdict

What’s working & what to watch

Watchouts 5

  • Profitability15/100

    -680% net margin · -1073% ROE

  • Cash flow16/100

    -597% free-cash-flow margin

  • Balance sheet18/100

    Current ratio 1.21

  • Volatility20/100

    Weak vs peers

  • Growth29/100

    Rev -4.1% CAGR · earnings -23.5%

Model-based scoring. For information only — not financial advice.

What is Renalytix AI plc?

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 14.64M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (36)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap14.64M
P/E RatioN/A
Dividend YieldN/A
52 Week High11.75
52 Week Low3.225
Last AnnualJune
IPO DateN/A
IncorporatedUK
Shares Outstanding437M
No. of Employees46
IndustryHealth Information Services
ExchangeLSE
Beta1.799
CurrencyGBX · Reports in USD
Websiterenalytix.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.